Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.68 |
| ▸ | ABL1 | P00519 | 2/20 | 0.67 |
| ▸ | RAF1 | P04049 | 2/20 | 0.67 |
| ▸ | LYN | P07948 | 2/20 | 0.67 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.67 |
| ▸ | BRAF | P15056 | 1/20 | 0.67 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.67 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.67 |
| ▸ | AKT1 | P31749 | 1/20 | 0.67 |
| ▸ | SRC | P12931 | 14/20 | 0.52 |
| ▸ | GSK3A | P49840 | 15/20 | 0.51 |
| ▸ | SYK | P43405 | 7/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4095732 | 0.89 | MAPK14 (0.77) | MAPK14ABL1RAF1LYNMAPK9 | |
| SCHEMBL4092835 | 0.85 | ABL1 (0.78) | MAPK14ABL1RAF1LYNMAPK9 | |
| SCHEMBL4081714 | 0.84 | ABL1 (0.77) | MAPK14ABL1RAF1LYNMAPK9 | |
| SCHEMBL4092801 | 0.84 | MAPK14 (0.78) | MAPK14ABL1RAF1LYNMAPK9 | |
| SCHEMBL6428327 | 0.84 | MAPK14 (0.62) | MAPK14ABL1RAF1LYNMAPK9 | |
| SCHEMBL4086564 | 0.84 | ABL1 (0.80) | MAPK14ABL1RAF1LYNMAPK9 | |
| SCHEMBL6053406 | 0.84 | ABL1 (0.82) | MAPK14ABL1RAF1LYNMAPK9 | |
| SCHEMBL6599887 | 0.83 | ABL1 (0.80) | MAPK14ABL1RAF1LYNMAPK9 | |
| SCHEMBL4081446 | 0.83 | ABL1 (0.82) | MAPK14ABL1RAF1LYNMAPK9 | |
| SCHEMBL6298768 | 0.83 | ABL1 (0.79) | MAPK14ABL1RAF1LYNMAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148555-A1 | Methods of treating COPD and pulmonary hypertension | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148555-A1 | Methods of treating COPD and pulmonary hypertension | PTGIS, PTGS1, MAPKAPK5 | MAPK14 55/4885ABL1 2764/4885RAF1 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.